Biotechnology Market Size, Share, Trends, and Forecast 2025–2033

The global Biotechnology Market )size reached USD 761.5 Billion in 2024 and is expected to grow to USD 1,315.9 Billion by 2033. The market is projected to expand at a CAGR of 6.27% during the forecast period from 2025 to 2033. Growth is driven by advancements in genetic engineering, personalized medicine research, and increasing demand for sustainable agriculture solutions.

STUDY ASSUMPTION YEARS

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

BIOTECHNOLOGY MARKET KEY TAKEAWAYS

• Current Market Size: USD 761.5 Billion in 2024
• CAGR: 6.27% (2025-2033)
• Forecast Period: 2025-2033
• Biotechnology applies molecular and cellular biological processes to industries including healthcare, agriculture, and environmental management.
• Innovation in gene editing, personalized medicine, and sustainable farming methods are primary market growth drivers.
• Healthcare dominates the application segment, spearheading advancements in diagnostics and treatment.
• North America holds the largest market share, supported by strong R&D investment and regulatory frameworks.
• Market players focus on biopharmaceuticals, CRISPR gene editing, AI integration in drug discovery, and sustainable biotech solutions.

Sample Request Link:

https://www.imarcgroup.com/biotechnology-market/requestsample

MARKET GROWTH FACTORS

The biotechnology market growth is primarily driven by rapid advancements in genetic engineering technologies, such as CRISPR-Cas9. This revolutionary gene-editing technique enables precise modifications within organisms, facilitating breakthroughs in medicine for gene therapies targeting genetic disorders and cancers. Additionally, engineered microbes produce valuable pharmaceutical compounds like insulin, transforming drug manufacturing processes. These innovations have broadened applications across healthcare, agriculture, and industrial processes, marking genetic engineering as a core catalyst for biotechnology market expansion.

Another major factor propelling the biotechnology market is the increasing demand for personalized medicine and therapeutics. Genomic sequencing advancements allow detailed analysis of an individual's genetic makeup to identify disease-linked variations. This capability supports the development of targeted therapies, including monoclonal antibodies and gene therapies, which improve treatment efficacy and safety. Diagnostics using genetic biomarkers enable early disease detection and prognosis, making healthcare more precise and individualized, thus substantially driving market growth.

Sustainable agriculture solutions are increasingly adopted due to the global demand for food and environmental concerns. Biotechnology supports genetically modified crops engineered for higher yield, pest resistance, and enhanced nutritional content. Biopesticides derived from natural organisms reduce environmental impact compared to chemical alternatives. Furthermore, biotechnology tools improve crop resilience to climate change and nutrient efficiency, contributing to food security and sustainable resource use. This expanding need for ecological agricultural practices is a significant market growth driver throughout the forecast period.

MARKET SEGMENTATION

Breakup by Product Type:

• Instruments: Provide the foundation for precise research and diagnostics, enabling accurate analyses and experiments.
• Reagents: Essential components fueling experimental research processes and facilitating reliable results.
• Software and Services: Include data analysis, visualization tools, consulting, training, and technical support to enhance biotechnological operations.

Breakup by Technology:

• Nanobiotechnology: Combines nanoscale materials with biological systems to revolutionize drug delivery, diagnostics, and therapies.
• Tissue Engineering and Regeneration: Develops novel methods for creating functional tissues to address organ shortages and medical needs.
• DNA Sequencing: Enables comprehensive genomic analysis essential for personalized medicine and disease understanding.
• Cell-Based Assays: Offer insights into cellular behavior supporting drug development and toxicity testing.
• Fermentation: Core bioprocessing method for producing biofuels, pharmaceuticals, and enzymes.
• PCR Technology: Amplifies DNA sequences vital for diagnostics and genetic research.
• Chromatography: Facilitates precise biomolecule separation critical for drug purification and analysis.
• Others: Include other biotechnological technologies not specified.

Breakup by Application:

• Healthcare: Dominates the market; biotechnology innovations improve diagnostics, personalized treatment, and patient care.
• Food and Agriculture: Biotechnology enhances crop yield, pest resistance, and nutritional content.
• Natural Resources and Environment: Utilizes biotechnology for sustainable ecological management.
• Industrial Processing: Applies biotechnology in manufacturing and processing industries.
• Bioinformatics: Integrates information technology and biotechnology to optimize research and development.
• Others: Additional applications not specifically categorized.

REGIONAL INSIGHTS

North America dominates the biotechnology market due to its robust ecosystem of research and innovation, strong R&D investments, and well-established regulatory frameworks. Leading universities, research institutions, and biotech companies foster continuous scientific and technological advancements. The region’s emphasis on entrepreneurship and venture capital accelerates the commercialization of biotech innovations. This dominance significantly shapes the global biotechnology landscape, driving growth, innovation, and positive socio-economic impact.

RECENT DEVELOPMENTS & NEWS

In May 2025, Biogen and City Therapeutics partnered to develop RNA interference (RNAi) therapies targeting central nervous system diseases. City Therapeutics provides the RNAi platform, and Biogen leads clinical development and commercialization. In May 2025, Biocon Biologics launched a biosimilar injectable treatment for psoriasis and psoriatic arthritis in Japan. April 2025 saw Novartis committing USD 23 Billion over five years to expand its US biotech footprint, while Amgen invested an additional USD 900 Million to expand its Ohio manufacturing site. In March 2025, Roche opened the Roche Genentech Innovation Center in Boston to lead R&D in cardiovascular and metabolism diseases and AI-driven drug discovery.

KEY PLAYERS

• Amgen Inc.
• Biocon Limited
• Biogen Inc.
• F. Hoffmann-La Roche AG
• Genmab A/S
• Lonza Group AG
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Seagen Inc.
• Syngenta AG
• Vertex Pharmaceuticals Incorporated

CUSTOMIZATION NOTE

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as part of the customization.

ABOUT US

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

CONTACT US

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302